Integrated Diagnostics Holdings PLC Notice of Results (8081K)
30 Agosto 2023 - 3:57AM
UK Regulatory
TIDMIDHC
RNS Number : 8081K
Integrated Diagnostics Holdings PLC
30 August 2023
Integrated Diagnostics Holdings Plc Notice of Results
30 August 2023
(London) Integrated Diagnostics Holdings ("IDH," "the Group," or
"the Company"), a leading provider of diagnostic services with
operations in Egypt, Jordan, Nigeria, Sudan, and soon launching in
Saudi Arabia, will publish its reviewed financial statements for
the six-month period ended 30 June 2023 on Thursday, 31 August 2023
at 7am (UK).
An analyst and investor call will be hosted at 1pm (UK) | 3pm
(Egypt) on Monday, 4 September 2023. You can register for the call
by clicking on this link .
For more information about the event, please contact:
amoataz@EFG-HERMES.com
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading diagnostics services provider in the Middle
East and Africa offering a broad range of pathology and radiology
tests to patients in Egypt, Jordan, Sudan and Nigeria. The Group's
core brands include Al Borg, Al Borg Scan and Al Mokhtabar in
Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan
(both in Sudan) and Echo-Lab (Nigeria). A long track record for
quality and safety has earned the Company a trusted reputation, as
well as internationally recognised accreditations for its portfolio
of over 2,000 diagnostics tests. From its base of 552 branches as
of 31 December 2022, IDH served over 8.7 million patients and
performs more than 32.7 million tests in 2022. IDH will continue to
add laboratories through a Hub, Spoke and Spike business model that
provides a scalable platform for efficient expansion. Beyond
organic growth, the Group's expansion plans include acquisitions in
new Middle Eastern, African, and East Asian markets where its model
is well-suited to capitalise on similar healthcare and consumer
trends and capture a significant share of fragmented markets. IDH
has been a Jersey-registered entity with a Standard Listing on the
Main Market of the London Stock Exchange (ticker: IDHC) since May
2015 with a secondary listing on the EGX since May 2021 (ticker:
IDHC.CA). Learn more at idhcorp.com .
The person responsible for arranging the release of this
announcement is Nancy Fahmy, Investor Relations Director at
IDH.
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORKZGFRRGKGFZG
(END) Dow Jones Newswires
August 30, 2023 04:57 ET (08:57 GMT)
Integrated Diagnostics (LSE:IDHC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Integrated Diagnostics (LSE:IDHC)
Gráfica de Acción Histórica
De May 2023 a May 2024